This trial is active, not recruiting.

Conditions hypoglycemia, diabetes mellitus
Treatment glucagon
Phase phase 3
Sponsor Locemia Solutions ULC
Start date March 2015
End date August 2015
Trial size 50 participants
Trial identifier NCT02402933, AMG109


Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of AMG504-1 in treating episodes of hypoglycemia.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
3 mg glucagon powder
glucagon dry-mist nasal glucagon
3 mg glucagon powder

Primary Outcomes

Proportion of Patients Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration
time frame: Within 30 minutes after dosing

Secondary Outcomes

Assessment of Ease-of-use of Dry-Mist Nasal Glucagon by Completion of Questionnaires by the Caregiver
time frame: After each dosing
Assessment of Local Tolerability from the Patient's Perspective
time frame: Within 2 hours of full recovery

Eligibility Criteria

Male or female participants from 4 years up to 17 years old.

Inclusion Criteria: - Availability for the entire study period. - Motivated Child/Adolescent with diabetes (C/AWD) and caregiver(s) and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the qualified investigator or designee. - C/AWD lives with one or more caregivers who are available to administer the glucagon in case of an episode of severe or moderate hypoglycemia. - Male or female C/AWD with a history of type 1 diabetes >1 year. - C/AWD aged of at least 4 years of age but less than 18 years. - A female C/AWD must meet one of the following criteria: a) Participant is of child-bearing potential and agrees to use one of the accepted contraceptive regimens throughout the entire duration of the study (from the pre-trial evaluation and enrollment visit until study completion). An acceptable method of contraception includes one of the following: (i) Abstinence from heterosexual intercourse (ii) Systemic contraceptives (birth control pills, injectable/implantable/ insertable hormonal birth control products, transdermal patch) (iii) Intrauterine device (iv) Condom with spermicide, OR b) Participant is of non-child-bearing potential, defined as a female who had had a hysterectomy or tubal ligation, is clinically considered infertile or has not yet reached menarche. - In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the Investigator is a suitable candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations. - Willingness to adhere to the protocol requirements. Exclusion Criteria: - Females who are pregnant according to a positive urine pregnancy test, actively attempting to get pregnant, or lactating. - History of significant hypersensitivity to glucagon, or any related products as well as severe hypersensitivity reactions (such as angioedema) to any drugs. - Presence of cardiovascular, gastrointestinal, liver or kidney disease, or any other conditions which in the judgment of the investigator could interfere with the absorption, distribution, metabolism or excretion of drugs or could potentiate or predispose to undesired effects. - Presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma. - Use of daily systemic beta-blockers, indomethacin, warfarin or anticholinergic drugs. - Concomitant maintenance therapy with any drug that would influence the outcome of the trial, at the discretion of the Investigator and the Sponsor. - Regular consumption of 3 or more units of alcoholic beverages per day. - Current participation in another clinical trial, intent to enroll in another clinical trial during this clinical study or use of an Investigational Product (in another clinical trial) within the prior 30 days.

Additional Information

Official title A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-Of-Use of AMG504-1 Administered in the Home or School Environments for Treating Hypoglycemia in Children and Adolescents With T1D
Description This study proposes to evaluate the effectiveness of intranasal (IN) glucagon administered under clinical use conditions in treating episodes of hypoglycemia in persons with T1D. This study also aims to assess the ease with which caregivers can administer the experimental medication in treatment of hypoglycemic events.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Locemia Solutions ULC.